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Abstract
We have recently described that in an experimental model of atherosclerosis and in vascular smooth muscle cells (VSMCs)
statins increased the activation of the Smad pathway by transforming growth factor-b (TGF-b), leading to an increase in
TGF-b-dependent matrix accumulation and plaque stabilization. Angiotensin II (AngII) activates the Smad pathway and
contributes to vascular fibrosis, although the in vivo contribution of TGF-b has not been completely elucidated. Our aim was
to further investigate the mechanisms involved in AngII-induced Smad activation in the vasculature, and to clarify the
beneficial effects of statins on AngII-induced vascular fibrosis. Infusion of AngII into rats for 3 days activates the Smad
pathway and increases fibrotic-related factors, independently of TGF-b, in rat aorta. Treatment with atorvastatin or
simvastatin inhibited AngII-induced Smad activation and related-fibrosis. In cultured rat VSMCs, direct AngII/Smad pathway
activation was mediated by p38 MAPK and ROCK activation. Preincubation of VSMCs with statins inhibited AngII-induced
Smad activation at all time points studied (from 20 minutes to 24 hours). All these data show that statins inhibited several
AngII-activated intracellular signaling systems, including p38-MAPK and ROCK, which regulates the AngII/Smad pathway
and related profibrotic factors and matrix proteins, independently of TGF-b responses. The inhibitory effect of statins on the
AngII/Smad pathway could explain, at least in part, their beneficial effects on hypertension-induced vascular damage.
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Introduction
Hypertension causes structural changes in the arteries (vascular
remodeling) that involve alterations in cell growth, vascular
smooth muscle cell (VSMCs) hypertrophy and accumulation of
extracellular matrix (ECM) [1,2]. Among the factors involved in
these processes, AngII has a key influence in the architecture and
integrity of the vascular wall, by its role as a true cytokine that
regulates cell growth, inflammation and fibrosis [1–3].
The molecular mechanisms involved in AngII signaling are
complex, including activation of transcription factors, protein
kinases and redox process [1–3]. The Smad pathway is the main
signaling system of transforming growth factor-b (TGF-b), but
growing evidence suggests that other factors can directly activate
this intracellular pathway [4]. Several in vitro studies have shown
that AngII activates Smad pathway independently of TGF-b in
cultured VSMCs [5,6] and other cell types [7–9]. Infusion of
AngII into rats induced aortic Smad activation [5,6,10], but its
relation with TGF-b and vascular fibrosis has not been completely
elucidated. In VSMCs, AngII, after binding to AT1 receptors,
increases the phosphorylation of regulated-Smad (Smad2 or
Smad3) that binds to Smad4, then this complex is translocated
into the nucleus where it acts as a transcription factor and
upregulates Smad-dependent gene transcription, including fibrot-
ic-related genes, such as connective tissue growth factor (CTGF)
and collagens [5,6].
The inhibitors of the 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase (also called statins) exert beneficial effects
in cardiovascular diseases. Besides their well-known effects in
downregulation of circulating cholesterol, statins also exert
pleiotropic effects at the cellular level, regulating intracellular
signaling systems [11]. We have recently demonstrated that in
cultured VSMCs, statins increased TGF-b-mediated Smad
activation and upregulated TGF-b receptor type II expression,
leading to an increase of TGF-b-mediated responses, including
ECM upregulation [12]. There are few studies evaluating the in
vivo effect of statins on Smad pathway. In experimental models of
atherosclerosis in mice, atorvastatin activates Smad signaling and
increased collagen deposition in the atheroma plaques [12,13].
However, antifibrotic proterties of statins have been described,
such as inhibition of AngII-induced vascular fibrosis [14].
Our aim was to investigate the mechanisms involved in AngII-
induced Smad activation in the vasculature, and the effect of
HMG-CoA reductase inhibitors in this pathway. The investigation
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e14145of the molecular mechanisms involved in these processes could
lead to a better understanding of cardiovascular pathology and to
optimize therapeutic strategies.
Methods
Experimental studies
Systemic infusion of AngII (100 ng/kg per minute; subcutane-
ous osmotic minipumps; Alza Corp) was performed into male
Wistar rats of 3 months of age for 3 days. Some animals were also
daily treated with the HMG-CoA reductase inhibitors atorvastatin
and simvastatin (5 mg/Kg/day, dissolved in 0.1% methanol in the
drinking water), starting 48 h before AngII-infusion. Control
groups of animals without treatments were also evaluated. We
have studied 10 animals per group. Blood pressure was measured
by tail-cuff pletysmography. Neither atorvastatin nor simvastatin
modify blood pressure in AngII-infused rats (not shown). All
experimental procedures were approved by the Animal Care and
Use Committee of the Fundacio ´n Jimenez Diaz Institute,
according to the guidelines for ethical care of experimental
animals of the European Community (RD 223/88 MAPA and
609/86).
Cell cultures
VSMCs were obtained from thoracic aorta of Wistar rats by
collagenase method [15]. VSMC from passages 2 to 7 were used
showing .99% positive immunostaining against smooth muscle a-
actin (not shown). For experiments, cells at 80% confluence were
arrested by serum-starvation for 48 hours. Cells were pretreated
with Simvastatin (Sigma) or atorvastatin (kindly donated by Pfizer
Madrid, Spain) for 48 hours and then treated with 10
27 mol/L
AngII (Fluka, Sigma), for 20 minutes or 24 hours. For kinase
experiments, cells were incubated for 1 hour with the following
MAPK inhibitors: SB203580 (p-38 inhibitor; 10
26 mol/L), U0126
ethanolate (MEK1/2 inhibitor: 10
25 mol/L) (Promega), and
SP600125 (JNK inhibitor; 10
25 mol/L), from Stressgen Biorea-
gents Corp; or with the ROCK inhibitor Y-27632 and Fasudil
(10
26 mol/L; (TOCRIS), and then treated with 10
27 mol/L
AngII, or 1 ng/ml human recombinant TGF-b1 (Peprotech) for
20 minutes. None of the inhibitors or statins were toxic at the doses
used (evaluated by cell viability assay MTS-PMS, Promega),
neither modify Smad proteins levels or activation.
Protein studies
To quantify protein levels Western blot was done [12]. Equal
protein loading was determined by BCA method (Pierce). The
autoradiographs were scanned using the GS-800 Calibrated
Densitometer (Quantity One, Bio-Rad), and data was calculated
as n-fold over control. TGF-b1 protein levels were measured using
a commercial enzyme-linked immunoassay (ELISA) (Bioscience)
following the manufacturer’s instructions. TGF-b1 activity was
quantified by comparison with a standard curve using increasing
concentrations of human TGF-b1.
For in vivo studies, paraffin-embedded sections of rat aorta were
studied by immunohistochemistry. Briefly, after Antigen Retrieval
and blockade of endogenous peroxidase aorta sections were
incubated with primary antibodies overnight at 4uC. After
washing, slides were treated with the corresponding anti-IgG
biotinylated-conjugated secondary antibody (Amersham Biosci-
ence) followed by the avidin-biotin-peroxidase complex (Dako),
and 3,39-diaminobenzidine as chromogen. Sections were counter-
stained with Carazzi’s hematoxylin. The specificity was checked
by omission of primary antibodies and use of non-immune sera.
Immunohistochemistry was analized by Imagepro-plus, Media
Cybernetics; Inc. All samples were evaluated in a blinded fashion.
For each rat, the mean score value was obtained by evaluating 4
different high-power fields (x 20) per section.
For in vitro studies, immunocytochemistry was done in cells
growing in coverslips, fixed with Merckofix (Merck), treated with
0.1% Triton-X100 and incubated with primary antibodies
followed by ALEXA 488 labeled antibody. Nuclei were stained
with DAPI. The absence of primary antibody was the negative
control. Samples were mounted in Mowiol 40-88 and examined
by a laser scanning confocal microscope (Leika). The experiments
were done with 3 different cell culture preparations.
Antibodies employed were: pSmad2 (Cell signaling), Smad4
(Santa Cruz Biotechnology), tubulin (Sigma-Aldrich), fibronectin,
type I collagen and G3PDH (Millipore).
Southwestern histochemistry was done using the consensus
Smad sense (59-GAGTATGTCTAGACTGACAATGTAC -39)
probe and controls previously described [7].
Gene studies
Total RNA was isolated with Trizol method (Gibco) and gene
expression was analyzed by Real-time PCR, performed on ABI
Prism 7500 sequence detection PCR system (Applied Biosystems)
according to manufacturer’s protocol. Assay IDs used were
TGF-b: Rn00572010_m1, TIEG: Rn00579697_m1; CTGF:
Rn00573960_m1, plasminogen activator inhibitor-1 (PAI-1):
Rn00561717_m1; type I collagen: Rn00584426_m1; metallopro-
teinase-9 (MMP-9), Rn00579162_m1; tissue inhibitor of matrix
metalloproteinase-1 (TIMP-1), Rn00587558_m1; fibronectin:
Rn00569575_m1 (Applied Biosystems, Foster City, CA). Data
were normalized with 18S eukaryotic ribosomal RNA: 4210893E.
Each animal was evaluated independently and data were
expressed as mean6SEM as n-fold increase vs. control group.
Statistical analysis
Results throughout the text are expressed as mean6SEM. One-
way analysis of variance was used to determine differences
between agonist-treated groups and controls. When statistical
significance (p,0.05) was found, post-hoc Bonferroni or Dunnett
tests were used to identify group differences. Statistical analysis was
conducted using the SPSS statistical software, version 11.0 (SPSS).
Results
AngII directly, by a TGF-b independent mechanism,
activates Smad pathway and increases ECM-related
proteins in rat aorta
Previous studies have shown that AngII activates Smad
signaling pathway in rat aorta [5,6], but whether AngII-induced
Smad activation was a direct effect or mediated by endogenous
TGF-b production was not elucidated. After 3 days of AngII
infusion we have observed that there was no increase on aortic
mRNA or protein levels of TGF-b1 (Figure 1A and B), while
Smad pathway is activated (Figure 2), as described [5]. We also
evaluated the expression of TGF-b-inducible early gene-1 (TIEG),
one of the earliest events in TGF-b mediated Smad signalling [16].
In AngII-infused rats TIEG gene levels were not modified
(Figure 1A). These data indicate that Smad activation occurs
earlier than TGF-b upregulation, suggesting that in vivo AngII
directly activates the Smad pathway in the aorta.
Next, we have characterized the effect to AngII infusion for 3
days in the vascular wall evaluating ECM-related proteins. In
frozen samples of rat aorta, upregulation of the profibrotic factors
CTGF and PAI-1 was found at gene expression levels (Figure 3A).
Regarding ECM proteins, overexpression at mRNA levels of
Ang II/Smad in Fibrosis
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Aortic fibronectin deposition was found at 3 days of AngII infusion
(Figure 3C), while there was no change on type I collagen
deposition, observed by western blot (Figure 3D), and by sirius red
staining (not shown). The balance between synthesis and
degradation regulates ECM accumulation; a process controlled
by matrix metalloproteinases (MMPs) and their tissue inhibitors
(TIMPs). Gene levels of MMP-9, a collagen-degrading enzyme,
Figure 1. TGF-b is not upregulated in the aorta of AngII-infused rats. Rats were infused with AngII (100 ng/kg per minute, subcutaneously)
for 3 days. Some animals were also treated with simvastatin or atorvastatin (5 mg/Kg/day), starting 48 hours before AngII infusion. A. RNA was
isolated from frozen samples of rat aorta and gene expression was evaluated by real time and expressed as mean6SEM of 10 animals per group. B.
TGF-b protein levels were measured in aortic protein extracts by Elisa. Data are expressed as mean6SEM of 10 animals per group.
doi:10.1371/journal.pone.0014145.g001
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TIMP-1 expression levels, the main inhibitor of MMP-9 [17],
were upregulated (Figure 4A). The ratio of MMP-9/TIMP-1
indirectly defines MMP-9 activity [18]. As seen in figure 4B, in
AngII-infused rats the MMP-9/TIMP-1 ratio in aorta was around
0,4-fold showing a clear matrix accumulation environment. These
results show that AngII in vivo activates Smad pathway and
upregulates profibrotic factors and ECM proteins, by a TGF-b-
independent process.
Statins inhibits the activation of Smad pathway and the
upregulation of ECM-related proteins observed in the
aorta of AngII infused rats
To evaluate the effect of statins on AngII-induced Smad
activation, rats were treated with simvastatin or atorvastatin
(5 mg/Kg/day), starting 48 hours before AngII infusion and
studied after 3 days. Both statins diminished Smad activation
caused by AngII in the aorta, as observed by decreased levels of
phosphorylated Smad2 and Smad4 by immunohistochemistry
(Figure 2A and B). By Southwestern histochemistry we have
confirmed the inhibitory effect of statins on AngII/Smad
activation. In AngII-infused rats for 3 days, a nuclear blue
staining, indicating active Smad complexes that bind to a
consensus Smad sequence in DNA, was observed in many
vascular cells, while few positive cells were found in control,
simvastatin or atorvastatin treated samples (Figure 2C).
The overexpression of profibrotic factors and ECM components
observed in AngII-infused rats at gene and protein levels were
downregulated by treatment with simvastatin or atorvastatin
(Figure 3). Moreover, the MMP-9/TIMP-1 ratio was reverted to
levels observed in control rats (Figure 4). In contrast, there was no
differences on TGF-b aortic levels between controls, AngII-infused
Figure 3. Infusion of AngII for 3 days increases ECM-related proteins in rat aorta: Inhibitory effect of statins. Gene expression of
profibrotic factors CTGF and PAI-1 (A) or ECM proteins, fibronectin and type I procollagen (B) was evaluated by real time PCR. Figure C and D show a
representative Western blot and data of aortic fibronectin and type 1 collagen protein levels, respectively. Data are expressed as mean6SEM of 10
animals per group, *p,0.05 vs control; # p,0.05 vs AngII.
doi:10.1371/journal.pone.0014145.g003
Figure 2. AngII activates the Smad pathway in rat aorta: Inhibitory effect of statins. Aortic sections were studied by
immunohistochemistry using antibodies against phosphorylated Smad2 (p-Smad2) and Smad4. Figure A shows a representative immunohisto-
chemistry experiment and B the quantification expressed as mean6SEM of 10 animals studied per group, *p,0.05 vs control; #p,0.05 vs AngII. C.
Southwestern histochemistry evaluated Smad-dependent DNA binding activity. The arrow shows active nuclear Smad complexes that were mainly
found in AngII-infused samples (Magnification 2006).
doi:10.1371/journal.pone.0014145.g002
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statins diminished the direct (TGF-b-independent) activation of
Smad pathway by AngII and subsequent upregulation of ECM-
related factors in rat aorta.
Statins inhibits the Smad pathway activation by AngII in
cultured vascular smooth muscle cells
Preincubation of VSMCs with simvastatin significantly inhib-
ited, in a dose-dependent manner, AngII-induced Smad2
Figure 4. Regulation of matrix metalloproteinases and its inhibitors in the aorta of AngII-infused rats: Restoration by statins. A.
Gene expression of MMP-9 and TIMP-1 was evaluated by real time PCR and data are expressed as mean6SEM of 10 animals per group, *p,0.05 vs
control; # p,0.05 vs AngII. B. Evaluation of matrix balance by the ratio MMP-9 vs TIMP-1. Values higher or lower than 1 reflect degradation or
accumulation, respectively, of matrix proteins.
doi:10.1371/journal.pone.0014145.g004
Ang II/Smad in Fibrosis
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and B, western blot). By confocal microscopy, we have observed
that simvastatin also inhibited the nuclear localization of p-Smad2
caused by incubation with AngII for 20 minutes. As can be seen in
the overlaid images of Figure 5C, AngII-treated cells presented a
white tone in the nucleus indicating p-Smad2 nuclear localization.
This nuclear localization was inhibited by simvastatin. Similar
inhibitory effects were observed with atorvastatin (data not shown).
These results show that in cultured VSMCs statins also inhibited
AngII-induced Smad activation, at all times studied.
Molecular mechanisms involved on statins inhibition of
the AngII/Smad pathway
We have previously described that statins inhibit several AngII-
induced intracellular responses, including MAPK and RhoA/
ROCK activation [14]. To test whether statins inhibitory effect on
Smad was due to the modulation of these kinases a pharmaco-
logical approach in VSMCs was done. Only the p38 MAPK
inhibitor SB203580, but not extracellular signal-regulated ki-
nase1/2 (MEK/ERK) (U0126) or Jun N-terminal kinase (JNK)
(SP600125), diminished AngII-induced Smad2 phosphorylation
(Figure 6A). To assess the implication of the small G protein RhoA
in the AngII/Smad pathway activation, VSMCs were preincu-
bated for 1 hour with two selective inhibitors of serine/threonine
ROCK I and II (Y-27632 and Fasudil). ROCK inhibition
decreased the phosphorylation of Smad2 caused by AngII
(Figure 6A). These data clearly show that p38-MAPK and
RhoA/ROCK participates in AngII/Smad activation. The
above-described inhibitory effects could explain the molecular
mechanism involved in statins effect on the regulation of AngII/
Smad pathway in vascular cells.
We have recently demonstrated that statins enhace Smad
activation caused by TGF-b through the inhibition of RhoA and
its downstream kinase ROCK [12]. For this reason, we have
evaluated whether activation of RhoA/ROCK or MAPK cascade
could be involved in TGF-b/Smad activation in VSMCs. None
ROCK or MAPKs inhibitors modified the increased p-Smad2 in
response to TGF-b (Figure 6B), suggesting that TGF-b/Smad
activation is independent of these kinases.
Figure 5. Statins inhibit the AngII/Smad pathway in cultured vascular smooth muscle cells. Cells were pretreated with simvastatin (SV) for
48 hours before stimulation with AngII for 20 minutes (A, C) or 24 hours (B). Figures A and B show a representative Western blot and data as
mean6SEM of 3–6 independent experiments. *p,0.05 vs. control, #p,0.05 vs. AngII. Figure C shows a representative confocal microscopy
experiment of 3 independent observations.
doi:10.1371/journal.pone.0014145.g005
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PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e14145Figure 6. p38 MAPK and ROCK inhibition disminishes AngII mediated Smad2 phosphorylation in VSMCs. Cells were preincubated for
1 hour with the inhibitors before treatment with AngII (A) or TGF-b (B) for 20 minutes. Figure shows a representative Western blot and data as
mean6SEM of 5–6 independent experiments. *p,0.05 vs control; # p,0.05 vs AngII.
doi:10.1371/journal.pone.0014145.g006
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The data presented here demonstrate that AngII induces Smad
activation in the rat aorta by a direct, TGFb independent, process,
and regulates several Smad-dependent proteins involved in
vascular fibrosis. This study extends the previous in vitro data to
an in vivo model and remark the importance of AngII as a direct
activator of Smad and inducer of profibrotic factors involved in
pathological accumulation of EMC components in the vascula-
ture.
We have previously shown that infusion of AngII into rats for 3
days activates Smad pathway in the aorta [5], as we have
confirmed here. Previous studies have described that AngII
increases TGF-b synthesis in rat aorta after 7 days associated to
elevated Smad2 phosphorylation [10]. In the present study, we
have found that at 3 days of AngII infusion aortic TGF-b, both at
gene and protein levels, was not upregulated while Smad signaling
pathway was activated. Previous studies have shown that in
cultured VSMCs AngII caused a direct and rapid activation of
Smad pathway [5,6]. All these results show that AngII directly, by
a TGF-b-independent process, activates the Smad pathway both in
vivo and in vitro in the vasculature. In vitro studies have shown that
Smad pathway is involved in AngII-induced fibrosis. Smad7
overexpression inhibited AngII-induced CTGF, fibronectin and
collagen expression in VSMCs [5], and Smad2-siRNA prevented
type I collagen network formation induced by AngII [19]. CTGF
is an important mediator of ECM accumulation by AngII in the
vasculature [15]. The regulation of CTGF by AngII has been
extensively studied, involving activation of Smad, protein kinases
(MAPKs and ROCK) and redox process [15,20]. In cultured
VSMCs, TGF-b also induces CTGF production [4]. In rats
infused with AngII for 3 days, we have observed aortic CTGF, but
not TGF-b, upregulation at the same time of Smad activation.
Pharmacological inhibition of PAI-1 protects against AngII-
induced aortic remodeling [21]. We have found that PAI-1 is
another important profibrotic factor induced by AngII via Smad,
in a TGF-b indepedent manner. All these data suggest that CTGF
and PAI-1 are early profibrotic mediators of AngII-mediated
vascular fibrosis directly regulated by Smad pathway, by a TGF-b
independent process.
Several groups have characterized the histological changes
caused by systemic infusion of AngII into rodents at the vascular
wall. Only after 7 days of AngII infusion accumulation within the
arterial wall of ECM proteins, including collagens, fibronectin and
laminin, has been described [10,15]. AngII infusion for 6 days
increased aortic TIMP-1 expression in the absence of collagen
deposition [22]. The synthesis of collagen is a complex process,
regulated at gene and protein levels, including postraslational
modifications and cross-links, being the net collagen levels also
controlled by MMPs activity. We have observed elevated TIMP-1
gene levels, while MMP-9 mRNA levels were not modified,
showing that after 3 days of AngII infusion the balance between
ECM synthesis and degradation is shifted to matrix accumulation.
Fibronectin is another key component of the extracellular matrix,
overexpressed in hypertension-induced vascular damage [15,23].
We have observed increased aortic fibronectin levels at 3 days of
AngII infusion. In VSMCs, fibronectin release is increased by
AngII and regulated by TGF-b, CTGF [15] and Smad [5]. Our
data suggest that Smad and CTGF could be involved in the in vivo
upregulation of fibronectin caused by AngII. In summary, several
profibrotic factors and ECM related proteins are regulated by
AngII/Smad pathway, independently of endogenous TGF-b
synthesis, showing that direct activation of Smad by AngII is
involved in the onset of vascular fibrosis.
Another important point of the present study is the demonstra-
tion the statins inhibited AngII-induced direct Smad activation in
rat aorta. In cultured VSMCs statins also blocked the direct
AngII/Smad activation, observed at 20 min, supporting our in vivo
findings. Statins treatment downregulates profibrotic factors
(CTGF, PAI-1) and ECM-related proteins (fibronectin) induced
by AngII in rat aorta, and restores ECM synthesis/degradation
balance to a normal situation. These data suggest that blockade of
AngII/Smad pathway could be a mechanism involved in the
beneficial effects of statins on vascular fibrosis.
We have further investigated the molecular mechanisms
involved in the direct activation of AngII/Smad pathway, using
a pharmacological approach in cultured VSMCs. We have
observed that inhibition of p38 MAPK and ROCK participates
in the activation of AngII/Smad pathway. Statins, acting at
cellular level, inhibited several intracellular pathways. In partic-
ular, in VSMCs statins inhibited AngII-induced MAPK and
RhoA/ROCK activation [14,24]. All these data suggest that the
mechanisms involved in the inhibitory effect of statins on AngII/
Smad, could be due to the modulation of RhoA/ROCK and
MAPK activation.
Previous studies have demonstrated that statins down-regulate
vascular TGF-b over-production caused by AngII, both in vitro and
in vivo [14]. In VSMCs, AngII induced a long-term Smad
activation mediated by endogenous TGF-b synthesis [6]. In these
cells we have observed that simvastatin inhibited AngII-induced
Smad activation observed at 24 hours. In a model of chronic
AngII infusion for 2 weeks, we have previously shown that
atorvastatin inhibited vascular fibrosis and aortic TGF-b upregu-
lation [14], associated to Smad pathway inhibition (unpublished
observations). All these data suggest that statins inhibited AngII-
induced endogenous TGF-b synthesis and subsequent Smad
activation observed in long time studies. Our data is supported by
findings in a mice model of AngII-induced cardiac damage.
Treatment with another statin, pitavastatin, inhibited TGF-b
production and Smad2/3 phosphorylation in cardiac tissue and
exerts protective effects on cardiovascular remodeling, diminishing
myocardial interstitial fibrosis [25].
In contrast, the effect of statins on TGF-b/Smad regulation in
atherosclerosis is different. In the ApoE knockout mice model of
atherosclerosis we have recently found that atorvastatin increased
Smad3 phosphorylation and ECM-related proteins, including
CTGF, PAI-1 and type I collagen in the fibrous cap [12]. In
ApoE/LDLR double knockout mice atorvastatin also increased
phosphorylation of Smad2/3 in aortic endothelium covering
atherosclerosis lesions [13]. In cultured VSMCs statins enhance
Smad pathway activation by TGF-b leading to an increase in
TGF-b-dependent actions, including accumulation of ECM
proteins [12]. These data suggest that the protective effect of
statins in plaque stability could be due to the enhancement of
TGF-b/Smad pathway. We have recently observed that RhoA/
ROCK inhibition (by pretreatment for 48 hours with toxin C3 or
ROCK inhibitors) increases Smad activation caused by TGF-b,b y
a process mediated by the upregulation of TGF-b type II receptor
[12]. However, ROCK inhibition diminished AngII-induced
Smad2 phosphorylation. These data show that RhoA/ROCK
differentially regulates Smad activation elicited by AngII or TGF-
b, and its inhibition mimics statins effects.
Smad pathway is the main TGF-b signaling pathway [16,26].
TGF-b, through Smad2/4 signaling, contributes to vascular
remodeling by VSMC growth and ECM synthesis at sites of
vascular injury [27]. TGF-b/Smad2 regulates CTGF, as shown by
Smad7 overexpression and studies with CTGF promoter [5,28].
Although TGF-b/Smad is an important pathway in vascular
Ang II/Smad in Fibrosis
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VSMCs, TGF-b regulates PAI-1 expression by the EGFR/pp60(c-
src)/MEK-ERK pathway and independent of Smad2 activation
[29]. We have observed that TGF-b-induced Smad2 phosphor-
ylation was not modified by MAPKs inhibitors, confirming an
ERK-independent Smad2 pathway in VSMCs. All these results
indicates that statins differentially regulates Smad pathway
activation by AngII or TGF-b in the vasculature in different
pathological conditions.
TGF-b is implicated in many human fibrotic disorders. TGF-b
is one of the most potent inducers of ECM proteins in fibroblasts
and contributes to epithelial mesenchymal transition (EMT) in
different tissues [30,31]. Statins attenuates EMT in human tenon
fibroblasts and renal tubuloepithelial cells, by inhibition of MAPKs
activation, whereas Smad2/3 phosphorylation was preserved [32–
34]. In contrast, simvastatin abrogates activation of intestinal
fibroblasts by TGF-b through the inhibition of Smad activation
[35]. These data clearly show that the effect of statins on Smad
regulation depends on cell type and pathological condition.
Our in vivo data demonstrate that AngII directly activates Smad
pathway in the vessel wall and regulates several Smad-dependent
proteins involved in vascular fibrosis, by a direct, TGFb
independent process. Statins are known as one of the best option
for the treatment of cardiovascular diseases. The present study
demonstrates that two statins, atorvastatin and simvastatin,
inhibited AngII-mediated Smad activation, both in vivo, in rat
aorta, and in cultured VSMCs, showing an intracellular
mechanism of statins action that regulates vascular fibrosis. Our
data afford additional information to the well-established pleio-
tropic effects of statins and could explain part of the early
beneficial effects of statins observed in patients without high
cholesterol levels but with other risk factors [36].
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